Dr. Keegan is a cancer epidemiologist with primary research interests in studies of cancer outcomes, health disparities and cancer survivorship. She has undertaken numerous studies with population-based cancer registry data in the United States, both alone and linked to other administrative and clinical databases, to understand patterns of cancer treatment and outcomes. Dr. Keegan has also been involved with multiple studies examining patient experiences with cancer and patient-reported outcomes after cancer diagnosis. A focus of her research is in adolescent and young adult (AYA) oncology where her research has documented sociodemographic disparities in stage at diagnosis, treatment, access to specialized cancer center care, late effects and survival.
Hematology and Oncology
B.S., Physiology, UC Davis, Davis CA 1996
M.S., Wellness Management, Ball State University, Muncie IN 1999
Ph.D., Epidemiology, Stanford University School of Medicine, Stanford CA 2003
Internal Medicine Mentor Research Award, UC Davis Department of Internal Medicine, 2017
Dr. Anthony F. Phillips Research Award, University of California, Davis Children�s Hospital, Children's Miracle Network, 2016
The Steven G. AYA Cancer Research Fund, Poster Presentation Award, 2015
Invited Participant, Student Workshop of the Society for Epidemiological Research, Palm Springs CA, 2002
Phi Sigma Honor Society for research and academic excellence in Biological Sciences, UC Davis, 1996
To view Dr. Keegan's publications, please click here.
Abrahão R, Brunson AM, Kahn JM, Li QW, Wun T, Keegan THM. Second primary malignancy risk after Hodgkin lymphoma treatment among HIV-uninfected and HIV-infected survivors. Leuk Lymphoma. 2022 May;63(5):1091-1101. doi:10.1080/10428194.2021.2020775. Epub 2022 Jan 6. PMID:34989283.
Poh C, McPherson JD, Tuscano J, Li Q, Parikh-Patel A, Vogel CFA, Cockburn M, Keegan T. Environmental pesticide exposure and non-Hodgkin lymphoma survival: a population-based study. BMC Med. 2022 Apr 26;20(1):165. doi:10.1186/s12916-022-02348-7. PMID:35468782.
John EM, Koo J, Ingles SA, Keegan TH, Nguyen JT, Thomsen C, Terry MB, Santella RM, Nguyen K, Yan B. Predictors of urinary polycyclic aromatic hydrocarbon metabolites in girls from the San Francisco Bay Area. Environ Res. 2022 Apr 1;205:112534. doi:10.1016/j.envres.2021.112534. Epub 2021 Dec 10. PMID:34896321.
Abdelhadi OA, Pollock BH, Joseph JG, Keegan THM. Psychological distress and associated additional medical expenditures in adolescent and young adult cancer survivors. Cancer. 2022 Apr 1;128(7):1523-1531. doi:10.1002/cncr.34064. Epub 2022 Jan 10. PMID:35001391.
Abrahão R, Ribeiro RC, Malogolowkin MH, Wun T, Keegan THM. Early mortality and survival improvements for adolescents and young adults with acute promyelocytic leukemia in California: an updated analysis. Haematologica. 2022 Mar 1;107(3):733-736. doi:10.3324/haematol.2021.278851. PMID:34320784.
Mahajan A, Brunson A, Eldredge J, White RH, Keegan THM, Wun T. Incidence and Outcomes Associated with 6,841 Isolated Distal Deep Vein Thromboses in Patients with 13 Common Cancers. Thromb Haemost. 2022 Jan 17. doi:10.1055/a-1742-0177. Epub ahead of print. PMID:35038763.
Mahajan A, Brunson A, Adesina O, Keegan THM, Wun T. The incidence of cancer-associated thrombosis is increasing over time. Blood Adv. 2022 Jan 11;6(1):307-320. doi:10.1182/bloodadvances.2021005590. PMID:34649273.
Chu JN, Canchola AJ, Keegan THM, Nickell A, Oakley-Girvan I, Hamilton AS, Yu RL, Gomez SL, Shariff-Marco S. Evaluating the Impact of Social and Built Environments on Health-Related Quality of Life among Cancer Survivors. Cancer Epidemiol Biomarkers Prev. 2022 Jan;31(1):161-174. doi:10.1158/1055-9965.EPI-21-0129. Epub 2021 Nov 2. PMID:34728471.
GBD 2019 Adolescent Young Adult Cancer Collaborators. The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet O. 2022 Jan;23(1):27-52.